Logo-jrip
Submitted: 10 Nov 2022
Accepted: 12 Jan 2023
ePublished: 09 Feb 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2023;12(3): e32158.
doi: 10.34172/jrip.2023.32158

Scopus ID: 85166007409
  Abstract View: 1238
  PDF Download: 754

Meta-analysis

The effect of metformin administration on cancer-specific survival, overall survival, progression-free survival, and disease progression in renal cell carcinoma patients; a systematic review and meta-analysis

Hassan Nourmohammadi 1 ORCID logo, Tayebe Jamshidbeigi 2 ORCID logo, Zahra Abdan 3 ORCID logo, Diana Sarokhani 4 ORCID logo, Moloud Fakhri 5* ORCID logo, Shakiba Alaienezhad 6* ORCID logo

1 Department of Internal Medicine, Shahid Mostafa Khomeini Hospital, Ilam University of Medical sciences, Ilam, Iran
2 Department of Internal Medicine, Ilam University of Medical Sciences, Ilam, Iran
3 Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
4 Nickan Research Institute, Isfahan, Iran
5 Traditional and Complementary Medicine Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran
6 General Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
*Corresponding Authors: Moloud Fakhri, Email: mmfir@yahoo.com, , Email: m.fakhri@mazums.ac.ir; Shakiba Alaienezhad, Email: shakiba.alaie@gmail.com

Abstract

Introduction: The increase in the incidence of renal cell carcinoma (RCC) has been reported worldwide. The anti-cancer impacts of metformin on the various types of cancer have been observed in clinical studies. Therefore, this study aims to survey the effect of metformin use on RCC patients using systematic review and meta-analysis methods.

Materials and Methods: In this research, Cochrane, Web of Science, PubMed, Scopus databases, and Google Scholar web browser were searched using standard keywords. Data were analyzed with STATA 14 software. The significance level of tests P<0.05 was considered.

Results: The improvement in the progression-free survival (PFS) (HR: 0.72 [95% CI: 0.54, 0.94], P=0.169, I2=37.8%) and cancer-specific survival (CSS) (HR: 0.36 [95% CI: 0.18, 0.75], P=0.339, I2=7.5%) was observed in eight studies with 10404 patients affected by RCC. However, no significant statistical effect was observed on the improvement in the disease progression (OR: 1.10 [95% CI: 0.85, 1.42], P=0.326, I2=0%) and cancer overall survival (OS) (HR: 0.72 (95% CI: 0.51, 1.01), P=0.153, I2=43.1%).

Conclusion: This study showed metformin administration improved CSS and PFS in RCC patients. More studies are warranted on the effect of metformin on the improvement in disease progression and OS of cancer.

Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID= CRD42022369108; https://www.crd.york. ac.uk/prospero/display_record.php?ID=CRD42022369108).


Implication for health policy/practice/research/medical education:

The results of this study indicated that metformin affects the improvement in cancer-specific survival (CSS) and progressionfree survival (PFS) of the disease in patients with renal cell carcinoma (RCC). The usefulness of this drug was proved in this study. In contrast, no advantage or significant impact was observed in the disease progression and overall survival of cancer improvement. There were limited number of studies on this subject. In addition, in each of the reviewed studies, the effect of metformin on some of the following cases of CSS, overall survival, PFS, and disease progression was not mentioned, therefore, it is recommended further researchers on this aspect of metformin.

Please cite this paper as: Nourmohammadi H, Jamshidbeigi T, Abdan Z, Sarokhani D, Fakhri M, Alaienezhad S. The effect of metformin administration on cancer-specific survival, overall survival, progression-free survival, and disease progression in renal cell carcinoma patients; a systematic review and meta-analysis. J Renal Inj Prev. 2023; 12(3): e32158. doi: 10.34172/ jrip.2023.32158.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 1239

Your browser does not support the canvas element.


PDF Download: 754

Your browser does not support the canvas element.